A Very Young Adult Female Patient with Hepatitis B Flare: A Case Report

Andreas Agung Kurniawan, Ummi Maimunah


Hepatitis B virus (HBV) infection is a major global health problem. It can cause chronic infection and put people at high risk of death from cirrhosis and liver cancer. This study aims to present a case of chronic hepatitis B flare in a very young adult patient. An 18-year-old previously healthy female presented with jaundice developing in one week, following the previous complaints of nausea, vomiting, abdominal pain, loss of appetite, and tiredness for about three months. The patient had no risk factors for getting HBV infection, but her HBsAg-positive mother was probably an inactive HBV carrier. The hepatitis B serological testing revealed HBsAg positivity, anti-HBs seronegativity, HBeAg positivity, anti-HBe seronegativity, anti-HBc IgM seronegativity, and high levels of HBV DNA detected > 1.70 × 108 IU/mL. There was a sharp increase in serum ALT to ≥ 5-fold ULN. The abdominal ultrasonography revealed a hepatitis feature, unremarkable portal venous flow, and an extrahepatic biliary system. The liver transient elastography revealed 15.6 kPa of liver stiffness, which was in accordance with the F3-F4 fibrosis stage. These features were typical of a hepatitis B flare, the HBeAg-positive chronic hepatitis B, previously known as the immune reactive phase. A long-term nucleos(t)ide analog therapy was programmed with Tenofovir alafenamide 25 mg daily.


hepatitis B virus infection; chronic hepatitis b; immune reactive phase; flare


Global HIV Hepatitis and Sexually Transmitted Infections Programmes. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021, https://www.who.int/publications/i/item/9789240027077 (2021).

Razavi-Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology 2018; 3:383–403.

Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005;34:1329–39.

World Health Organization. Guideline for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015;124.

The Society for Adolescent Health and Medicine. Young adult health and well-being: a position statement of the society for adolescent health and medicine. Journal of Adolescent Health 2017; 60: 758–759.

The European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology 2017; 67: 370–398.

Janssen HLA, Fung S. Hepatitis B. In: Feldman M, Friedman LS, Brandt LJ, et al. (eds) Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, Eleventh Edition. Philadelphia: Elsevier, 2021, pp. 1309-1331.e4.

Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408–1415.

Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: From discovery to regulatory approval. Journal of Hepatology. 2017;67:847–61.

Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: New perspectives on an old concept. Cellular and Molecular Immunology. 2015; 12:258–263.

Jüngst C, Berg T, Cheng J, et al. Intrahepatic cholestasis in common chronic liver diseases. European Journal of Clinical Investigation 2013;43:1069–1083.

Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Springer India, 2016. Epub ahead of print 2016. DOI: 10.1007/s12072-015-9675-4.

Liaw Y ‐F, Tai D ‐I, Chu C ‐M, et al. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody‐positive patients. Hepatology. 1987;7:20–3.

Bonino F, Brunetto MR. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: An overview. Journal of Hepatology 2003;39:160–3.

Liaw YF, Yang SS, Chen TJ, et al. Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. Journal of Hepatology 1985;1:227–233.

Liaw YF, Chu CM, Su IJ, et al. Clinical and histological events preceding hepatitis B antigen seroconversion in chronic type B hepatitis. Gastroenterology. 1983; 84:216–9.

Maurya M, Munshi R. Prognosis of severe acute flares of chronic hepatitis B. Exploratory Research and Hypothesis in Medicine 2022; 000: 000–000.

Liaw YF, Chu CM. Hepatitis B virus infection. The Lancet 2009;373:582–92.

Liaw YF. Hepatitis B flare after cessation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B: To retreat or not to retreat. Hepatology 2021;73:843–852.

Liaw YF. Stopping nucleos(t)ide analogue therapy in hbeag-negative chronic hepatitis B. Gastroenterology 2020;159:1186.

Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clinical Gastroenterology and Hepatology 2010;8:541–5.

Hoofnagle JH. Reactivation of hepatitis B. Hepatology; 49. Epub ahead of print 2009. DOI: 10.1002/hep.22945.

Wells JT, Perrillo R. Hepatitis B. In: Feldman M, Friedman LS, Brandt LJ (eds) Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, 10th Edition. Philadelphia: Elsevier Saunders, 2016. p. 1309-1331.e4.

Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound in Medicine and Biology 2003; 29: 1705–1713.

de Lédinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterologie Clinique et Biologique 2008;32:58–67.

Mazur R, Celmer M, Silicki J, et al. Clinical applications of spleen ultrasound elastography – a review. Journal of Ultrasonography 2018;18:37–41.

Reddy S, Weinberg L, Young P. Crystalloid fluid therapy. Critical Care; 20. Epub ahead of print 2016. DOI: 10.1186/s13054-016-1217-5.

Ovadia C, Sajous J, Seed PT, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. The Lancet Gastroenterology and Hepatology 2021;6:547–58.

Wijaya I. The role of ursodeoxycholic acid in acute viral hepatitis: an Evidence-based case report. Acta Med Indones. 2015;47:352–7.

Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology. 2019;70: 172–93.

Send SR. Nutritional Management of Cholestasis. Clinical Liver Disease; 15.

Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for chronic hepatitis B. New England Journal of Medicine 2008;359 2442–2455.

Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Digestive Diseases and Sciences 2015; 60: 1457–1464.

Chan HL, Fung S, Seto WK, et al. Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. Journal of Hepatology 2017;66:S25.

Chen R, Zou J, Long L, et al. Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B. Frontiers in Medicine; 8. Epub ahead of print January 17, 2022. DOI: 10.3389/fmed.2021.796901.

Full Text: PDF


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.